Pyrazinamide Resistance among Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates in Myanmar

The emergence and spread of multidrug-resistant tuberculosis (MDR-TB) have been a serious threat in the control of TB. This situation has been augmented by the emergence of more-severe extensively drug-resistant tuberculosis (XDR-TB). MDR-TB strains have become resistant to all fluoroquinolones (FQ; specifically, ofloxacin, levofloxacin, moxifloxacin, and gatifloxacin) and all of the second-line injectable drugs (amikacin, capreomycin, and kanamycin). In Myanmar, TB incidence was estimated at 365/100,000 population, and there were 2,793 laboratory-confirmed cases of MDR-TB and rifampin-resistant TB and 11 laboratory-confirmed cases of XDR-TB in 2015 (1). Pyrazinamide (PZA) is a standard component of short-course anti-TB treatment regimens and also of second-line regimens for MDR-TB and XDR-TB (2, 3). PZA is also one component of new regimens: novel rifampin-sparing anti-TB regimens and a shorter MDR-TB treatment regimen (4). There are limited data on PZA resistance because routine drug susceptibility testing (DST) has rarely been performed due to technical difficulties (5, 6). We identified PZA resistance in 66 clinical MDR-TB isolates which were collected at the Yangon and Mandalay TB Centers during 2015 and 2016. Those isolates were used for phenotypic PZA DST by the BACTEC 960 mycobacterial growth indicator tube (MGIT 960) (Becton, Dickinson, Sparks, MD) system at the concentration of 100 g/ml, and the Mycobacterium tuberculosis H37Rv strain was used as the reference strain (7). Mutations in the pncA gene and its promoter region (pncA region) were identified using DNA sequencing to determine genotypic resistance to PZA. The 756-bp pncA gene was sequenced with forward (CGGATTTGTCGCTCACTACA) and reverse (TCCGCCGCCGAACAGTTCATCCCGGT) primers using an ABI 3500XL genetic analyzer (Applied Biosystems, USA). The wild-type pncA gene from M. tuberculosis H37Rv (Gene ID 888260) was used as the reference sequence, and sequences were aligned using Bioedit version 7.2. 6.1 (http://www.mbio.ncsu.edu/BioEdit/bioedit.html). Analysis of the sequences was performed on the basis of sequences in the available literature and online databases (8, 9, 10). Of 66 MDR-TB isolates from Myanmar, 40 (60.6%) were PZA resistant and all of them showed mutations in the pncA region. There was good concordance between phenotypic PZA DST and sequencing results (0.968 kappa coefficient). This finding coincides with those of other studies (6, 11). Forty different types of mutations were distributed in the pncA region, and 10 types were first found in this study. We found 10 FQ-resistant pre-XDR and 7 XDR strains among 40 PZA-resistant isolates (Table 1). A recent multicountry survey reported 3.0 to 42.1% PZA resistance among patients with rifampin resistance (12). Our study showed relatively higher PZA resistance (60.6%) among MDR-TB isolates, and some of them were XDRand pre-XDR-TB strains. This Accepted manuscript posted online 20 December 2017 Citation Aung WW, Ei PW, Nyunt WW, Htwe MM, Win SM, Aye KT, Mon AS, Aung ST, Chang CL, Lee JS. 2018. Pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Myanmar. Antimicrob Agents Chemother 62:e01984-17. https://doi.org/10.1128/AAC.01984-17. Copyright © 2018 American Society for Microbiology. All Rights Reserved. Address correspondence to Jong Seok Lee, cosmosljs@gmail.com. LETTER TO THE EDITOR